Low-grade gliomas: Management issues

Expert Review of Anticancer Therapy

Volumn 7, Issue 12 SUPPL., 2007, Pages

  Duran, Isis ^a   Raizer, Jeffrey J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chemotheraphy; Gliomas; Low grade; Radiation therapy; Surgery

Indexed keywords

CARBOPLATIN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

BLOOD VOLUME; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CHROMOSOME MUTATION; CLINICAL TRIAL; COGNITIVE DEFECT; COMPUTED TOMOGRAPHY SCANNER; DIAGNOSTIC VALUE; GLIOMA; HEADACHE; HUMAN; LABORATORY TEST; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PERFUSION WEIGHTED IMAGING; PERSONALITY DISORDER; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION DOSE; REVIEW; SEIZURE; SURVIVAL TIME; SYMPTOMATOLOGY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 38049146436     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.12.S15     Document Type: Review

References (62)

1. van Veelen ML, Avezaat CJ, Kros JM, van PW. Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation and the issue of early versus late surgery. J. Neurol. Neurosurg. Psychiatr. 64, 581-587 (1998).
2. Wessels PH, Weber WE, Raven G et al. Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol. 2, 395-403 (2003).
3. Leighton C, Fisher B, Bauman G et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J. Clin. Oncol. 15, 1294-1301 (1997).
4. Henson JW, Gaviani P, Gonzalez RG. MRI in treatment of adult gliomas. Lancet Oncol. 6, 167-175 (2005).
5. Barker FG, Chang M, Huhn SL et al. Age and the risk of anaplasia In magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 80, 936-941 (1997).
6. Shaw E, Arusen R, Scheithauer B et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J. Clin. Oncol. 20, 2267-2276 (2002).
7. Kreth FW, Faist M, Rossner R, Volk B, Ostertag CB. Supratentorial World Health Organization grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. Cancer 79, 370-379 (1997).
8. Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am. J. Neuroradiol. 21, 1645-1649 (2000).
9. Pirzkall A, Nelson SJ, McKnight TR et al. Metabolic imaging of low-grade gliomas with 3D magnetic resonance spectroscopy. Int. J. Radiat. Oncol. Biol. Phys. 53, 1254-1264 (2002).
10. Law M, Yang S, Wang H et al. Glioma grading: sensitivity, specificity and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am. J. Neuroradiol. 24, 1989-1998 (2003).
11. Cha S, Tihan T, Crawford F et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am. J. Neuroradiol. 26, 266-273 (2005).
12. Padma MV, Said S, Jacobs M et al. Prediction of pathology and survival by FDG PET in gliomas. J. Neurooncol. 64, 227-237 (2003).
13. Catalaa I, Henry R, Dillon W P et al. Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. NMR Biomed. 19, 463-475 (2006).
14. Lote K, Egelan T, Hager B et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J. Clin. Oncol. 15, 3129-3140 (1997).
15. Laws ER Jr, Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J. Neurosurg. 61, 665-673 (1984).
16. Bauman G, Lote K, Larson D et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int. J. Radiat. Oncol. Biol. Phys. 45, 923-929 (1999).
17. Pignatti F, Bent M, van den Bent M et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J. Clin. Oncol. 20, 2076-2084 (2002).
18. Schuurman PR, Troost D, Verbeeten B Jr, Bosch DA. 5-year survival and clinical prognostic factors in progressive supratentorial diffuse 'low-grade' astrocytoma: a retrospective analysis of 46 cases. Acta Neurochir. (Wien.) 139, 2-7 (1997).
19. Piepmeier JM, Fried I, Makuch R. Low-grade astrocytomas may arise from different astrocyte lineages. Neurosurgery 33, 627-632 (1993).
20. Kleihues P, Cavanee WK. WHO Classificiation: Tumors of the Nervous System. Kleihus P and Cavanee WK (Eds). IARC Press, Lyon, France (2000).
21. Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J. Clin. Oncol. 24, 1246-1252 (2006).
22. Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J. Clin. Oncol. 18, 636-645 (2000).
23. Hoang-Xuan K, Capelle L, Kujas M et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 57,1278-1281 (2001).
24. Lavon I, Zrihan D, Zelikovitch B et al. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin. Cancer Res. 13, 1429-1437 (2007).
25. Ohgaki H, EibL RH, Wiestler OD et al. p53 mutations in nonastrocytic human brain tumors. Cancer Res, 51, 6202-6205 (1991).
26. Jenkins RB, Blair H, Ballman KV et al. A t (1:19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66, 9852-9861 (2006).
27. van den Bent MJ, Afra D, O de Wittle et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366, 985-990 (2005).
28. Shaw EG, Dumas-Duport C, Scheithauer BW et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J. Neurosurg. 70, 853-861 (1989).
29. Ulmer JL, Salvan CV Mueller WM et al. The role of diffusion tensor imaging in establishing the proximity oftumor borders to functional brain systems: implications for preoperative risk assessments and postoperative outcomes. Technol. Cancer Res. Treat. 3, 567-576 (2004).
30. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J. Neurosurg. 95, 735-745 (2001).
31. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74, 1784-1791 (1994).
32. Schmidt MH, Berger MS Lamborn KR et al. Repeated operations for infiltrative low-grade gliomas without intervening therapy. J. Neurosurg. 98, 1165-1169 (2003).
33. Recht LD, Lew R, Smith TW. Suspected low-grade glionma: is deferring treatment safe? Ann. Neunol. 31, 431-436 (1992).
34. Karim AB, Maat B, Hatlevoll R et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int. J. Radiat. Oncol. Biol. Phys. 36, 549-556 (1996).
35. Karim AB,Afra D, Cornu P et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J. Radiat. Oncol Biol. Phys. 52, 316-324 (2002).
36. Fisher BJ, Leighton CC, Vujovic O, Macdonald DR, Stitt L. Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J. Radiat. Oncol. Biol. Phys. 51, 704-710 (2001).
37. Vigliani MC, Sichez N, Poisson M, Delattre JY. A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int. J. Radiat. Oncol. Biol. Phys. 35, 527-533 (1996).
38. Kiebert GM, Curran D, Aaronson NK et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised Phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J. Cancer 34, 1902-1909 (1998).
39. Surma-aho O, Niemela M, Vikki J et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56, 1285-1290 (2001).
40. Postma TJ, Klein M. Vertappen CC et al. Radiotherapy induced cerebral abnormalities in patients with low-grade glioma. Neurology 59, 121-123 (2002).
41. Correa DD, Deangelis LM, Shi W et al. Cognitive functions in low-grade gliomas: disease and treatment effects. J. Neurooncol. 81, 175-184 (2007).
42. Taphoorn. MJ, Schiphorst AK, Snoek FJ et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol. 36, 48-54 (1994).
43. Klein M, Heimans JJ, Aaronson NK et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360, 1361-1368 (2002).
44. Laack NN, Brown PD, Ivnik RJ et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int. J. Radiat. Oncol. Biol. Phys. 63, 1175-1183 (2005).
45. Eyre HJ, Crowley JJ, Townsend JJ et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg. 78, 909-914 (1993).
46. Shaw EG, Berkey B, Coons SW et al. Initial report of Radiation Therapy Oncology Group (RTOG) 9802: prospective studies in adult low-grade glioma (LGG). J. Clin. Oncol. 24, S18 (2006).
47. van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neurooncology Group. Neurology 51, 1140-1145 (1998).
48. van den Bent MJ, Keime-Guibert F, Brandes AA et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 57, 340-342 (2001).
49. Pace A. Vidiri A, Galie E et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann. Oncol. 14, 1722-1726 (2003).
50. van den Bent MJ, Chinot O, Boogerd W et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group Phase II study 26972. Ann. Oncol. 14, 599-602 (2003).
51. Quinn JA, Reardon DA, Friedman AH et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J. Clin. Oncol. 21, 646-651 (2003).
52. Soffietti R, Nobile M, Ruda R et al. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine and vincristine) chemotherapy: a Phase II study. Cancer 100, 807-813 (2004).
53. Levin N, Lavon I, Zelikovitsh B et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106, 1759-1765 (2006).
54. van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J. Clin. Oncol. 21, 2525-2528 (2003).
55. Brandes AA, Tosoni A, Cavallo G et al. Temozolomide (TMZ) 3 weeks on/1 week off in the treatment of progressive low grade gliomas: a Phase II GICNO study. J. Clin. Oncol. 24, S18 (2006).
56. Stege EM, Kros JM, de Bruin HG et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103, 802-809 (2005).
57. Mason WP. Krol GS, Deangelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 46, 203-207 (1996).
58. Buckner JC, Gesme D Jr, O'Fallon IR et al. Phase II trial of procarbazine, tomustine and vincristine as initial therapy for patients with low-grade oligodendroglioma or ligoastrocytoma: efficacy and associations with chromosomal abnormalities. J. Clin. Oncol. 21, 251-255 (2003).
59. Hoang-Xuan K, He J, Huguet S et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome I p deletions. J. Clin. Oncol. 22, 3133-3138 (2004).
60. Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J. Neurooncol. 82, 281-288 (2007).
61. Lebrun C, Fontaine D, Bourg V et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur. J. Neurol. 14, 391-398 (2007).
62. Kaloshi G, Benouaich-Amiel A, Diakite F et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68, 1831-1836 (2007).